Camurus Expands Share Capital After Employee Stock Option Exercises

Camurus AB ( (SE:CAMX) ) just unveiled an announcement.

Camurus AB, a biopharmaceutical company specializing in long-acting treatments for severe and chronic conditions, develops its drug candidates using its proprietary FluidCrystal technology and maintains a diversified pipeline in dependence, pain, cancer, and endocrine diseases. The Sweden-headquartered group operates across key global markets and is listed on Nasdaq Stockholm under the ticker CAMX.

The company reported that 54,550 employee stock options under its ESOP 2022/2026 program were exercised in February 2026, resulting in the issuance of an equal number of new shares. Following this increase, Camurus’ total share count and voting rights rose from 59,880,184 to 59,934,734, a modest dilution that marginally expands the shareholder base while reflecting employee participation in the firm’s long-term incentive scheme.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK620.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

More about Camurus AB

Camurus AB is an international, science-led biopharmaceutical company focused on developing and commercializing innovative long-acting medicines for severe and chronic diseases. Its products are based on proprietary FluidCrystal technology, with an R&D pipeline spanning dependence, pain, cancer, and endocrine disorders, and operations across Europe, the U.S., and Australia.

Average Trading Volume: 140,627

Technical Sentiment Signal: Hold

Current Market Cap: SEK30.63B

See more data about CAMX stock on TipRanks’ Stock Analysis page.